All News

A panel of oncologists, pharmacists, and physician assistants discussed prevalent regimens for patients with recurrent endometrial cancer.

The SkinJect data set found about an 80% overall response rate for patients with nodular basal cell carcinoma receiving 200µg of doxorubicin microneedle array.

Results from the phase 1/2 ReFocus trial demonstrated positive activity from lirafugratinib in the various pretreated, FGFR2-mutated cholangiocarcinoma populations.

Experts discussed the clinical implications of the LITESPARK-011 trial of belzutifan plus lenvatinib following a presentation of efficacy findings at ASCO GU.

Three experts in surgery, radiation, and integrative care disclosed the most salient advances and keen insights in their respective fields.

Experts discuss the evolution of rectal cancer care from the use of “cookie cutter” approaches to the growth of personalized treatment pathways.

Jesse Fann, MD, MPH, spoke about what he hopes to accomplish during the 2-year term of his APOS presidency.

The latest clinical insights on endometrial cancer management were highlighted during a round table discussion.

Experts in genitourinary oncology outlined factors to consider when sequencing immunotherapy, tyrosine kinase inhibitors, and other RCC therapies.

A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

Phase 3 ENVISION trial data revealed a 72.2% probability of remaining event-free among responders to UGN-102 with non-muscle invasive bladder cancer.

Patients with stage IIA to IIIA NSCLC identified as low risk per LAMPAD criteria may be candidates for treatment de-escalation with nivolumab.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.

ONCOLOGY has identified FDA approvals that have affected the oncology treatment paradigm over the last 40 years.

Julian Hong, MD, MS, offered strategies for providing mental health services into routine workflows for patients undergoing anti-cancer treatment.

About 50% to 60% of Lambert-Eaton myasthenic syndrome cases occur secondary to a malignancy, most commonly small cell lung cancer, and 3% of patients with SCLC have LEMS.

Data from the phase 3 TOP trial support a potential molecular risk–guided treatment strategy for EGFR-mutant advanced NSCLC.

Soft tissue sarcomas are a rare but heterogeneous group of tumors accounting for less than 1% of all cancers.

Linda E. Carlson, PhD, RPsych, asserted mindfulness programs have strong evidence in managing psychosocial symptoms, but require increasing access for use.

Berzosertib plus cisplatin and radiotherapy did not meet the preliminary efficacy end point of complete response rate in this head and neck cancer group.

Data from the Lung-Care Project showed that non–high-risk patients experienced better survival and curative potential through early detection.

In the phase 3 KEYNOTE-590 trial, the PD-L1 IHC 22C3 pharmDx (Code SK006) companion diagnostic was used to evaluate PD-L1 status in tumor specimens.

Today the patient-physician relationship that Pergament et al outlined in 1999 is even more prevalent, driven by the rapid development, use, and uptake of social media across all oncology fronts.

Linda Carlson, PhD, RPsych, explored the shift from efficacy to implementation in integrative oncology, emphasizing behavioral interventions.

Yesne Alici, MD, discussed cancer-related fatigue and cognitive impairment and addressed sleep disturbances and AEs such as anemia to improve outcomes.

Low-grade toxicity related to durvalumab in the ASTEROID trial was common, which mostly consisted of skin reactions, pruritus, and fatigue.

Clinically relevant variants were detected in 64% of samples, with negative results informing response or ruling out central nervous system lymphomas.

Adding atezolizumab to adjuvant FOLFOX significantly improves disease-free survival for patients with stage III mismatch repair-deficient colon cancer.

Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.